Semaglutide other names: what the different brands actually mean

Step 1: recognise that the drug is the same, but the licence is not

Semaglutide is a GLP-1 receptor agonist. It slows gastric emptying, reduces appetite signals, and influences blood-sugar regulation through a single hormonal pathway. Eli Lilly did not make it; Novo Nordisk did, and Novo Nordisk holds every one of its UK authorisations. What changes between the brands is the strength, the delivery method, and (most importantly) the licensed population the medicine has been assessed and approved for.

Ozempic contains semaglutide at 0.5 mg, 1 mg and 2 mg doses administered by weekly injection. Its UK licence covers adults with type 2 diabetes. It has never been licensed here for weight management, and the MHRA is clear on this point. If someone suggests you use Ozempic because it is the same drug as Wegovy, that framing is incomplete: the licences are different, and a prescriber writing Ozempic for weight loss would be doing so off-label.

Rybelsus is semaglutide in tablet form at 3 mg, 7 mg and 14 mg doses, again licensed for type 2 diabetes only. These strength numbers matter: they are sometimes confused with the Wegovy tablet's own dose ladder, which runs 1.5 mg, 4 mg, 9 mg and 25 mg. The two sets of numbers belong to different products for different conditions. You can read more about how the different semaglutide drug names and their licences compare in our dedicated reference.

Step 2: understand which name means weight management in the UK

Wegovy (the injection) was the first semaglutide brand licensed in the UK specifically for weight management. Its dose ladder runs from 0.25 mg up to 2.4 mg weekly, titrated over roughly four to five months. In April 2026 the MHRA approved a dedicated single-dose 7.2 mg pen, available for adults with a BMI of 30 or above; starting at 0.25 mg and stepping up to 7.2 mg represents the highest dose of semaglutide approved anywhere in the UK. The Wegovy overview at nume covers the full licensed picture.

Then came the Wegovy tablet. On 11 June 2026, the MHRA approved oral semaglutide co-formulated with an absorption enhancer as the UK's first oral GLP-1 medicine for weight management, and the UK was the first country in Europe to grant that approval. The dose ladder is 1.5 mg, 4 mg, 9 mg and 25 mg, taken once daily on an empty stomach with a small amount of plain water, at least 30 minutes before food or any other oral medicine. No refrigeration is needed, which some patients find genuinely easier to manage when travelling or over the Christmas break. The NHS has not yet commissioned this treatment; it is available only via private prescription for now.

Both Wegovy formats are licensed for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure or high cholesterol. Lower BMI thresholds apply for certain ethnic backgrounds under UK guidance. The semaglutide treatment guide explains how the two formats differ day to day.

Step 3: check what the evidence says about Wegovy's weight-loss results

The phase 3 evidence for Wegovy's weight management indication comes from the STEP trials. In STEP 1, published in the New England Journal of Medicine, adults treated with semaglutide 2.4 mg lost around 15% of their body weight on average over 68 weeks alongside lifestyle support. For context, the placebo group lost around 2.4% over the same period.

The newer oral formulation was studied in the OASIS 4 trial (307 adults, 64 weeks). Average weight reduction was around 13.6% compared with approximately 2.4% for placebo. Among participants who remained fully adherent to the tablet protocol, that average rose to roughly 17%. Those figures come from Novo Nordisk's UK approval announcement and represent the canonical quoted values, framing the higher number as an adherence-dependent result, not a headline average, keeps the picture accurate.

Neither figure is a guarantee. Trial populations are selected, conditions are controlled, and individual responses vary. A prescriber reviews whether treatment is appropriate for you specifically, including any medicines that could interact with daily oral semaglutide or weekly injections. If you are weighing up which format might suit you better, the different Wegovy names and formats page covers that comparison.

Step 4: know the one name to treat with caution, Ozempic for weight loss

Because Ozempic contains semaglutide and has been widely discussed in the press alongside Wegovy, many people arrive at a pharmacy asking for it by name with weight management in mind. The NHS medicines page for semaglutide is explicit: Ozempic is licensed for type 2 diabetes, not weight loss. That distinction matters for safety and for supply. Ozempic shortages over 2023 and 2024 arose partly because demand for weight-management purposes diverted stock away from people who needed it for diabetes. The NHS semaglutide medicines page sets out the licensed indications plainly.

For anyone looking at the cost of weight management with semaglutide, the Wegovy cost guide gives a factual picture of how private pricing works and what an all-inclusive price should cover. Legitimate private treatment includes the clinical consultation, the prescription, and supported follow-up, not just the pen or tablet itself.

The other name for semaglutide guide goes into further detail if you have come across a product name you do not recognise and want to check whether it has UK approval. Our Wegovy other name page covers the same question from the brand's angle.

If after reading this you think Wegovy (injection or tablet) might be right for you, speaking to a prescriber is the natural next step. Check your eligibility through a free consultation, reviewed the same day by a real clinician at our GPhC-registered pharmacy (registration number 9012878, verifiable at the GPhC register).